PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
5.86%
Operating income growth 5-10% – Moderate. Peter Lynch would evaluate product-level profitability to see if certain segments could accelerate growth.
-142.73%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-120.58%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-120.58%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
10.21%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
10.21%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
9.39%
OCF growth 5-10% – Moderate. Peter Lynch would consider if new products or expansions could drive bigger OCF improvements.
9.37%
FCF growth 5-10% – Moderate. Peter Lynch might expect further expansion if the company’s revenue and margins keep improving.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
-5186.83%
A negative 5Y OCF/share CAGR indicates declining cash generation per share mid-term. Benjamin Graham would see this as a red flag unless explained by short-term strategic investments.
-34380.15%
Negative 3Y OCF/share CAGR shows recent erosion in operating cash. Benjamin Graham would see this as a cautionary signal unless explained by strategic investments.
-67208.18%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-8163.79%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
-121.82%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
31995.75%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
9371.92%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
10880.98%
3Y equity/share CAGR above 12% – Excellent recent net worth expansion. Warren Buffett would check consistent earnings retention or beneficial buybacks driving this growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Asset growth above 20% – Rapid expansion. Warren Buffett checks if returns justify this investment and if debt finances it unsafely.
28.45%
Book value/share growth above 12% annually – Strong sign of compounding. Warren Buffett verifies if profits or buybacks mainly drive it.
-51.38%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
-5.21%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
-6.73%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.